Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis Biosplice’s Phase 2b trial for lorecivivint hits primary endpoint in osteoarthritis pain SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of its successful Phase 2b knee osteoarthritis clinical trial data in Osteoarthritis and Cartilage. In this 24-week clinical trial, Biosplice’s groundbreaking knee OA drug candidate, lore...
Source: forextv.com